3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
38
Recurrence
6
Neoplasms, Plasma Cell
4
Small Cell Lung Carcinoma
3
Lymphoma
3
Ovarian Neoplasms
2
Disease
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Plasma Cell
1
Leukemia
1
Kidney Neoplasms
1
Immunoglobulin Light-chain Amyloidosis
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Graft vs Host Disease
1
Esophageal Neoplasms
1
Amyloidosis
1
Interventions
romidepsin
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Vincristine
4
Gemcitabine
4
Doxorubicin
4
Cyclophosphamide
4
Prednisone
3
Lenalidomide
3
Azacitidine
3
10-propargyl-10-deazaaminopterin
3
pembrolizumab
2
ixazomib
2
fludarabine phosphate
2
copanlisib
2
Whole-Body Irradiation
2
Vitamin B 12
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mycophenolic Acid
2
Folic Acid
2
Etoposide
2
Dexamethasone
2
Cyclosporine
2
Bortezomib
2
venetoclax
1
tislelizumab
1
tazemetostat
1
relatlimab
1
prednisolone phosphate
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, T-Cell, Peripheral
×
carfilzomib
×
Clear all
NCT03141203
2022-05-18
RomiCar
University of Birmingham
Phase 1/2
Completed
50 enrolled